A method for predicting the efficacy of an anti-PD-1 antibody or anti-PD-L1 antibody therapy, a method for evaluating the malignancy of cancer, and a method for increasing the efficacy of an anti-PD-1 antibody or anti-PD-L1 antibody therapy

摘要

An object of the present invention is to provide a method for predicting the efficacy of an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a novel biomarker, and a method for evaluating the malignancy of cancer. The method for predicting the efficacy of an anti-PD-1 antibody or anti-PD-L1 antibody therapy for a subject according to the present invention comprises the steps of: measuring the LAT1 expression level in a sample collected from the subject's cancer tissue; A step of predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy for a subject based on the level is provided. A method for evaluating the malignancy of a subject's cancer is based on a step of staining a sample collected from a subject's cancer tissue with an anti-LAT1 antibody and an anti-PD-L1 antibody, and the presence or absence of LAT1-positive and PD-L1-positive sites. The process of evaluating the malignancy of a test subject's cancer is provided.